GKOS — Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Company profile
- Sector: Healthcare
- Industry: Medical - Devices
- Country: US
- Exchange: NYSE
- Employees: 995
- Website: https://www.glaukos.com
Latest SEC filings for GKOS
- 8-K — 2026-08-03
- 8-K — 2026-07-29
- 10-Q — 2026-07-29
- 8-K — 2026-06-03
- 8-K — 2026-05-04
- 10-Q — 2026-04-30
- 8-K — 2026-04-29
- ARS — 2026-04-16
- SCHEDULE 13G/A — 2026-03-26
- 8-K — 2026-03-02
Latest GKOS news
- — INSP Stock Gains 47.8% in Three Months: What's Driving the Rally? (Zacks Investment Research)
- — DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally? (Zacks Investment Research)
- — BDX Stock Gains 25.5% in Six Months: What's Behind the Rally? (Zacks Investment Research)
- — Forge’s Fierce Life Sciences Announces 2026 Fierce Innovation Awards Finalists and Unveils the Fierce Vanguard Gala (GlobeNewswire Inc.)
- — Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? (Zacks Investment Research)
- — Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally? (zacks.com)
- — Glaukos: The Second J-Code Rewrites The Risk Math (seekingalpha.com)
- — Glaukos' iDose TR meets primary goal in phase 4 trial (seekingalpha_market)
- — Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal (Zacks Investment Research)
- — Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal (zacks.com)
Educational tool only — not investment advice.